Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of serum S100a8/9 complex level in diagnosis and prognosis of acute myocardial infarction

A technology of acute myocardial infarction and complex, applied in the field of medicine and biology, can solve the problem of not reflecting the characteristics of ischemia-reperfusion injury, etc.

Active Publication Date: 2018-12-11
BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Existing markers mainly reflect non-specific pathological mechanisms such as neutrophil activation, inflammation, endothelial cell activation, and cell necrosis after AMI, and cannot reflect the pathological changes characteristic of ischemia-reperfusion injury

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of serum S100a8/9 complex level in diagnosis and prognosis of acute myocardial infarction
  • Application of serum S100a8/9 complex level in diagnosis and prognosis of acute myocardial infarction
  • Application of serum S100a8/9 complex level in diagnosis and prognosis of acute myocardial infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Example 1: Differences in S100a8 / 9 expression levels between AMI patients and healthy individuals

[0055] According to the principle of gender and age matching, serum samples of 207 healthy people and 208 AMI patients were selected, and the expression level of S100a8 / 9 was detected by ELISA experiment. The expression level of S100a8 / 9 in AMI patients was 1.91 times higher than that in healthy people (P<0.001).

[0056] 1. Experimental steps:

[0057] Kit: R&D Systems, Inc, Human S100A8 / S100A9, Heterodimer Immunoassay

[0058] (1) Reagent preparation:

[0059] 1. Equilibrate all reagents to room temperature before use.

[0060] 2. Wash Buffer: If crystals have formed in the concentrated solution, equilibrate to room temperature and shake gently until the crystals are completely dissolved, then add ionized water or distilled water to dilute 20ml of the wash buffer to 500ml.

[0061] 3. Substrate Solution: Chromogenic reagents A and B should be mixed in equal volumes ...

Embodiment 2

[0084] Example 2: The expression of S100a8 / 9 at two consecutive time points in 210 AMI patients before PCI and 1 day after PCI

[0085] 210 AMI patients PCI preoperative (0 day), postoperative 1 day (1 day), continuous 2 time point samples, detect the expression level of S100a8 / 9 protein complex in the patient's serum by the ELISA experiment identical with embodiment 1 .

[0086] 1. The detection results of the expression level of S100a8 / 9 at 1 day after operation are shown in figure 2 , Table 2, the results showed that the expression level of S100a8 / 9 after PCI was higher than that before PCI (P<0.001).

[0087] Table 2. Serum S100a8 / 9 protein complex content of patients before and after PCI

[0088]

Embodiment 3

[0089] Example 3: Prognostic value of S100a8 / 9 on in-hospital MACE events

[0090] According to the occurrence of MACE events (death, acute heart failure) in the hospital, 210 AMI patients were divided into MACE group (35 people) and Non-MACE group (175 people). The expression level of the S100a8 / 9 protein complex in the patient's serum was detected by the same ELISA experiment as in Example 1.

[0091] Statistics show:

[0092] ① Differences in the expression of the S100a8 / 9 complex between the MACE group and the Non-MACE group before PCI (0 day) and 1 day after PCI (1 day). At 1 day after operation, there was a significant statistical difference between the two groups, and the MACE group was 1.57 times higher than the Non-MACE group (P image 3 and Table 3.

[0093] Table 3. Serum S100a8 / 9 protein complex content of patients in MACE group and Non-MACE group before and after PCI

[0094]

[0095] ②A logistic regression model was established to illustrate the relationship...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of serum S100a8 / 9 complex level in diagnosis and prognosis of acute myocardial infarction. The prognosis is characterized by predicting conditions of prognosis ofAMI patients after percutanecus coronary intervention and distinguishing the patients into a group with high risk of postoperative adverse events and a group with low risk of postoperative adverse events; the adverse events comprise and are not limited to death and acute heart failure.

Description

technical field [0001] The invention belongs to the technical field of medicine and biology, and specifically relates to an application of serum S100a8 / 9 complex level in the diagnosis and prognosis judgment of acute myocardial infarction. Background technique [0002] With economic and social development, changes in people's lifestyles, and the acceleration of population aging, the incidence of cardiovascular diseases in my country is on the rise. According to the "China Cardiovascular Report 2015" data, there are 290 million patients with cardiovascular diseases in my country, including 2.5 million patients with acute myocardial infarction. Acute myocardial infarction (AMI) is one of the more serious types of coronary heart disease, which can often lead to a series of serious cardiovascular events. AMI mostly occurs on the basis of coronary atherosclerotic stenosis. Due to some incentives, the coronary atherosclerotic plaque ruptures, and the circulating platelets gather ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/558G01N33/535
CPCG01N33/535G01N33/558G01N33/6893G01N2800/324G01N2800/56G01N2333/4727G01N33/54306
Inventor 杜杰李玉琳
Owner BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com